LAPAROSCOPY AND DOXORUBICIN INJECTION SURGERY SUPERFICIAL BLADDER CANCER TREATMENT AT YEN BAI PROVINCE GENERAL HOSPITAL

Abstract

This study aims to evaluate the results of laparoscopic tumor resection surgery and Doxorubicin injection to treat superficial bladder cancer at Yen Bai Provincial General Hospital. We performed a retrospective description of 31 patients with superficial bladder cancer who underwent initial endoscopic tumor resection and postoperative Doxorubicin injection between January 2018 and December 2023. The results showed that the average age of the subject group was 58.58 ± 8.9 years old; Men make up the majority (83.9%), women (16.1%), the male/female ratio is 5.2/1. The most common symptom is hematuria in 25/31 patients (80.1%). Preoperative diagnostic ultrasound detected 20/31 patients (64.5%). CT Scanner can detect tumors in 100% of patients. Cystoscopy results showed that the majority of patients had a tumor, 20/31 (64.5%). The average surgical time was 42.7 ± 11.8 minutes. There were 1/31 patients with bleeding complications after surgery (3.2%). Postoperative pathology showed that the invasive stage was mainly T1 in 19/31 patients (61.3%). Evaluation of results when discharged from the hospital was Good 96.8% (30 cases), average 3.2% (1 case). 100% of patients were supplemented with Doxorubicin pump, 20/31 patients (64.5%) complied with treatment. Follow-up recurrence after 1 year was 2/31 patients (6.5%). From there, it was found that treating superficial bladder cancer with laparoscopic tumor resection and Doxorubicin injection is a safe and effective method.